tiprankstipranks
Trending News
More News >
Duality Biotherapeutics, Inc. (HK:9606)
:9606
Hong Kong Market

Duality Biotherapeutics, Inc. (9606) Ratios

Compare
3 Followers

Duality Biotherapeutics, Inc. Ratios

HK:9606's free cash flow for Q2 2025 was ¥0.48. For the 2025 fiscal year, HK:9606's free cash flow was decreased by ¥ and operating cash flow was ¥0.10. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
4.73 0.49 0.52
Quick Ratio
4.73 0.49 0.52
Cash Ratio
3.46 0.31 0.44
Solvency Ratio
-2.02 -0.25 -0.13
Operating Cash Flow Ratio
0.99 0.07 0.32
Short-Term Operating Cash Flow Coverage
13.49 0.00 0.00
Net Current Asset Value
¥ 2.83B¥ -2.20B¥ -1.29B
Leverage Ratios
Debt-to-Assets Ratio
0.02 <0.01 <0.01
Debt-to-Equity Ratio
0.02 >-0.01 >-0.01
Debt-to-Capital Ratio
0.02 >-0.01 >-0.01
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00
Financial Leverage Ratio
1.43 -1.03 -1.33
Debt Service Coverage Ratio
-5.66 -4.17K -1.87K
Interest Coverage Ratio
-144.20 -755.97 4.16K
Debt to Market Cap
<0.01 0.00 0.00
Interest Debt Per Share
1.63 0.07 0.07
Net Debt to EBITDA
8.27 1.20 5.71
Profitability Margins
Gross Profit Margin
41.83%40.42%76.06%
EBIT Margin
-21.17%-52.25%-11.31%
EBITDA Margin
-20.70%-51.84%-11.03%
Operating Profit Margin
-0.51%-9.74%43.74%
Pretax Profit Margin
-149.43%-52.26%-11.32%
Net Profit Margin
-149.74%-54.11%-20.01%
Continuous Operations Profit Margin
-149.74%-54.11%-20.01%
Net Income Per EBT
100.21%103.54%176.77%
EBT Per EBIT
29019.01%536.82%-25.88%
Return on Assets (ROA)
-61.24%-50.25%-23.84%
Return on Equity (ROE)
-443.72%51.95%31.81%
Return on Capital Employed (ROCE)
-0.27%10.61%-73.62%
Return on Invested Capital (ROIC)
-0.26%10.63%-130.49%
Return on Tangible Assets
-61.82%-51.39%-24.73%
Earnings Yield
-20.89%-6.56%-2.31%
Efficiency Ratios
Receivables Turnover
5.72 5.12 17.72
Payables Turnover
1.49 1.72 1.82
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
94.65 104.40 100.60
Asset Turnover
0.41 0.93 1.19
Working Capital Turnover Ratio
0.53 -1.22 -1.74
Cash Conversion Cycle
-181.13 -140.45 -179.81
Days of Sales Outstanding
63.80 71.27 20.60
Days of Inventory Outstanding
0.00 0.00 0.00
Days of Payables Outstanding
244.92 211.73 200.41
Operating Cycle
63.80 71.27 20.60
Cash Flow Ratios
Operating Cash Flow Per Share
20.50 3.44 9.81
Free Cash Flow Per Share
20.26 3.06 9.38
CapEx Per Share
0.24 0.37 0.43
Free Cash Flow to Operating Cash Flow
0.99 0.89 0.96
Dividend Paid and CapEx Coverage Ratio
85.00 9.17 22.74
Capital Expenditure Coverage Ratio
85.00 9.17 22.74
Operating Cash Flow Coverage Ratio
12.60 54.03 153.50
Operating Cash Flow to Sales Ratio
0.50 0.15 0.46
Free Cash Flow Yield
3.27%1.59%5.05%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-4.79 -15.25 -43.22
Price-to-Sales (P/S) Ratio
15.13 8.25 8.65
Price-to-Book (P/B) Ratio
4.20 -7.92 -13.75
Price-to-Free Cash Flow (P/FCF) Ratio
30.58 62.90 19.80
Price-to-Operating Cash Flow Ratio
14.32 56.04 18.93
Price-to-Earnings Growth (PEG) Ratio
0.49 -0.08 5.74
Price-to-Fair Value
4.20 -7.92 -13.75
Enterprise Value Multiple
-64.80 -14.72 -72.69
Enterprise Value
22.92B 14.81B 14.32B
EV to EBITDA
-64.80 -14.72 -72.69
EV to Sales
13.42 7.63 8.02
EV to Free Cash Flow
27.12 58.17 18.35
EV to Operating Cash Flow
26.80 51.83 17.55
Tangible Book Value Per Share
68.90 -24.86 -14.16
Shareholders’ Equity Per Share
69.84 -24.31 -13.51
Tax and Other Ratios
Effective Tax Rate
>-0.01 -0.04 -0.77
Revenue Per Share
40.96 23.34 21.48
Net Income Per Share
-61.33 -12.63 -4.30
Tax Burden
1.00 1.04 1.77
Interest Burden
7.06 1.00 1.00
Research & Development to Revenue
0.34 0.43 0.31
SG&A to Revenue
0.08 0.02 0.02
Stock-Based Compensation to Revenue
0.07 0.10 0.01
Income Quality
-0.34 -0.28 -4.04
Currency in CNY